Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Trial For Teva’s Laquinimod Hinges On SPA From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.


Related Content

Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11
MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?
Multiple Sclerosis Drug Category Heats Up; So Does Spending
Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
Disappointing BRAVO Data Raise Doubts About Laquinimod's Chances With FDA
No Homerun, But A Base Hit For Teva's Laquinimod


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts